Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Doximity ( (DOCS) ) is now available.
On June 10, 2025, Dr. Nathan Gross announced his decision to step down as Chief Strategy Officer of Doximity to transition into an advisory role effective June 16, 2025. Dr. Gross, a co-founder of the company, will continue to contribute his expertise under an Independent Contractor Agreement, with his stock options continuing to vest until September 2025. This transition marks a significant change in leadership but reflects confidence in Doximity’s strategic direction and its potential to become a generational company in the healthcare technology sector.
The most recent analyst rating on (DOCS) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on Doximity stock, see the DOCS Stock Forecast page.
Spark’s Take on DOCS Stock
According to Spark, TipRanks’ AI Analyst, DOCS is a Outperform.
Doximity’s strong financial performance is the most significant factor in its overall score, supported by robust revenue growth and profitability. The earnings call also adds positively due to strong operational highlights. However, the high P/E ratio and mixed technical indicators moderate the overall score, indicating both potential and risks.
To see Spark’s full report on DOCS stock, click here.
More about Doximity
Doximity operates in the digital health industry, providing a platform that focuses on doctor-centric technology solutions. The company is known for its innovative products in workflow, news, and AI, aiming to transform the healthcare industry while maintaining a ‘Physicians First’ approach.
Average Trading Volume: 2,638,773
Technical Sentiment Signal: Buy
Current Market Cap: $10.79B
See more insights into DOCS stock on TipRanks’ Stock Analysis page.